Bausch & Lomb Corp
At today's price, Bausch & Lomb Corp (BLCO) is priced for today's economics sustained for ~5.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Bausch and Lomb is a storied eye-health franchise in a leveraged turnaround: net debt of about 4.77 billion dollars at over 20 times operating income, with interest coverage near 0.5 times, so operations do not currently cover interest. New product launches are reaccelerating: Miebo dry-eye revenue grew 33 percent to 76 million dollars, and management raised full-year 2026 guidance to revenue of 5.42 to 5.52 billion and adjusted EBITDA of 1.01 to 1.06 billion. The price near 15 dollars sits be
Is BLCO overvalued? See what's priced in →
96 institutional managers reported holding BLCO in 13F filings for the quarter ended 2026-03-31. Together they hold about 11% of the company; the top 10 hold 7%. 17 opened new positions that quarter. Held by Icahn Capital, Oaktree Capital, D. E. Shaw, among others. On the short side, 4.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (8.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BLCO's share count grew 1.5% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BLCO over the trailing three years: 2024: 1 buy totaling $505k; 2025: 2 buys totaling $268k; 2026: 9 buys totaling $1.22M. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BLCO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-04 | +0.1% | +12.1% |
| 2023-08-03 | -2.5% | -9.1% |
| 2023-11-02 | +4.7% | -2.9% |
| 2024-05-02 | -4.7% | +5.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BLCO's latest 8-K filings: 2026-05-20 (items 5.07); 2026-04-29 (items 2.02, 9.01); 2026-02-18 (items 2.02, 9.01); 2026-01-02 (items 1.01, 2.03, 8.01, 9.01); 2025-12-17 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.